1. Case report {#s0005}
==============

1.1. Clinical presentation {#s0010}
--------------------------

This is a case report of a two and half-year old male with end stage renal disease (ESRD) secondary to obstructive uropathy on peritoneal dialysis who developed acute onset of hypercalcemia while on therapy with calcitriol and ergocalciferol for management of mineral and bone disorder related to chronic kidney disease (CKD-MBD). Patient was hospitalized for severe anemia and was noted to have acute onset of hypercalcemia (peak serum calcium- 15 mg/dl, ionized calcium -- 2.28 mmol/L) during the hospital admission. A low hemoglobin (6.1 mg/dl) was detected on routine laboratory testing in the outpatient clinic and he was admitted for a blood transfusion. He was otherwise asymptomatic.

1.2. Past medical history {#s0015}
-------------------------

Patient was diagnosed with posterior urethral valves at birth and developed significant deterioration of kidney function for which he was initiated on continuous cycling peritoneal dialysis (CCPD) therapy at five months of age. His other medical conditions related to ESRD include anemia, growth failure and malnutrition, hypertension and secondary hyperparathyroidism. Patient was on standard of care therapy with calcitriol to treat secondary hyperparathyroidism and ergocalciferol to treat vitamin D deficiency. Prior to admission, patient had normal PTH and calcium levels ([Table 1](#t0005){ref-type="table"}). In the outpatient clinic, calcitriol was started when PTH levels rose to 1458 ng/L and the dose titrated to maintain PTH levels between 150 and 300 ng/L. Due to longstanding biochemical abnormalities related to CKD-MBD, he developed severe bone deformities noted on X-Rays of the skeleton ([Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}): there was sclerosis in the proximal metadiaphysis of the proximal humerus bilaterally, proximal and distal metadiaphyses of the femurs bilaterally, sclerosis and bowing deformity of the radius, ulna, tibia and fibula bilaterally and metaphyseal cupping and fraying of the bilateral radii and ulnas consistent with rickets. These skeletal changes are classic for poorly controlled secondary hyperparathyroidism and CKD-MBD.Table 1Laboratory data at clinical diagnosis.Table 1Biochemistries1 month prior to admissionAt clinical presentationReference rangeCalcium10.8158.8--10.3 mg/dLIonized calcium--2.281.16--1.36 mmol/LPhosphorus--6.53.1--6.0 mg/dLAlbumin3.82.73.1--4.8 g/LBone specific alkaline phosphatase--10540--120 U/LPTH1741912--65 ng/L25OHD193420--50 ng/ml1,25(OH)~2~D--1131--87 pg/mlPTHrP--16\<2 pmol/LVitamin A--33020--43 μg/dlFig. 1Skeletal X-Ray of chest, abdomen and upper extremities. There is sclerosis in the proximal metadiaphysis of the proximal humerus bilaterally. There is sclerosis and bowing deformity and metaphyseal cupping and slight fraying of the radius and ulna.Fig. 1Fig. 2Skeletal X-Ray of lower extremities. There is sclerosis in the proximal and distal metadiaphyses of the bilateral femurs. There is sclerosis and bowing of the tibias and fibulas bilaterally.Fig. 2

1.3. Clinical findings {#s0020}
----------------------

Patient was asymptomatic with no h/o lethargy, constipation, weight loss or polydipsia. Differential diagnosis for hypercalcemia included vitamin D intoxication, incorrect dosing or accidental overdose of calcitriol. A full diagnostic workup was initiated ([Table 1](#t0005){ref-type="table"}). Anemia was attributed to inadequate erythropoietin therapy and the dose was adjusted during hospitalization. Hemoglobin improved with blood transfusion.

Home medication list: calcitriol 0.5 μg per gastrointestinal tube (G-Tube) twice a day, erythropoietin 1800 Units subcutaneously three times a week, ergocalciferol 3600 IU per G-Tube daily, ferrous sulfate 15 mg of elemental iron Per G Tube two times daily, folic acid-b complex-vitamin c (NEPHRONEX) 900 μg/5 mL, 1 ml per G-Tube daily, sevelamer carbonate 0.4 g per G-Tube three times daily with meals, sodium chloride 9 mEq by Per G Tube two times daily, somatropin 0.6 mg subcutaneously six times a week.

1.4. Diagnostic workup challenges and timeline {#s0025}
----------------------------------------------

One month prior to admission, patient had normal PTH and serum calcium levels ([Table 1](#t0005){ref-type="table"}). Shortly after admission, serum calcium increased from 9.6 mg/dl on day 1 to 15 mg/dl on day 5, and ionized calcium peaked at 2.28 mmol/L on day 5 on the same home dose of calcitriol. Given that there was no change in the medications, it was suspected that calcitriol was being administered infrequently at home or incorrectly via G-tube. With regular administration of calcitriol by nursing staff, it was thought that the patient was now responsive to calcitriol with increased intestinal absorption of calcium and subsequent hypercalcemia. Therefore, the working diagnosis for hypercalcemia was calcitriol overdose or vitamin D toxicity. Serum PTH, 25OHD and 1,25(OH)~2~D levels were drawn and both ergocalciferol and calcitriol therapy were discontinued. Given calcitriol half life is short (\~27 h in children) it was expected that serum calcium levels will normalize within a few days. However, 25OHD and 1,25(OH)~2~D levels were within normal range ruling out calcitriol overdose and vitamin D toxicity. Serum calcium levels remained elevated during hospital stay. PTH levels were appropriately suppressed at 19 ng/L ruling out parathyroid hormone related disorders and a more extensive workup for hypercalcemia was initiated. Urine calcium excretion was not measured because patient had ESRD with oliguria. Differential diagnosis at this time point included hyperthyroidism, adrenal insufficiency, hypercalcemia of malignancy, granulomatous diseases and vitamin A toxicity. Sarcoidosis is very rare in this age group and was not considered in the differential diagnosis. PPD test for tuberculosis was negative. Thyroid hormone and cortisol levels were within normal limits. Patient had significantly elevated N terminal PTHrP (16 pmol/L, normal \<2.0 pmol/L) and vitamin A levels (330 μg/dl, normal 20--43 μg/dL) ([Table 1](#t0005){ref-type="table"}). Patient\'s hospital stay was extended to investigate a malignancy that would cause an increased PTHrP production. MRI and CT scans of head, neck, chest and abdomen were negative for a malignant process. He had no evidence of a hematologic malignancy with a negative workup for lymphoma and leukemia.

1.5. Therapeutic intervention {#s0030}
-----------------------------

a.Pharmacologic intervention- Ergocalciferol and calcitriol were discontinued, patient received peritoneal dialysis with low calcium dialysate solution throughout admission. Serum calcium, PTH and PTHrP levels were monitored at regular intervals.b.Nutritional intervention-Patient\'s nutritional regimen was closely monitored by a renal dietician. With the onset of hypercalcemia, the volume of formula was decreased by 50% to decrease intestinal calcium load. For age, patient\'s daily calcium requirement was 700 mg per day. His original nutrition prescription provided 680 mg calcium per day before interventions were initiated to treat hypercalcemia. Vitamin A level was significantly high (330 μg/dL) but detailed review of his dietary intake showed his intake was 90% dietary reference intake (DRI) for vitamin A for his age and he did not receive any additional supplementation. Serum calcium levels decreased slightly with this nutritional intervention. However, due to concerns of inadequate macronutrient intake, his feeds were adjusted to provide an intake with normal calories and protein but with reduced calcium (140 kcal/kg, 2.1 g protein/kg, 295 mg calcium, 813 IU vitamin A and 21 IU vitamin D per day). His daily calcium intake ranged from 159 to 250 mg per day. Despite \~60% reduction in calcium intake, serum calcium level was 12.7 mg/dl at the time of hospital discharge. In the outpatient clinic, serum calcium remained elevated (10.6--13.0 mg/dl) for considerable length of time despite these measures. He received a deceased donor kidney transplant 5 months after presentation and serum calcium and PTHrP levels returned to normal values ([Table 2](#t0010){ref-type="table"}).Table 2Laboratory data during clinical course.Table 2BiochemistriesAt hospital discharge1 month after discharge2 months after dischargePost kidney transplantReference rangeCalcium12.712.111.08.98.8--10.3 mg/dLIonized calcium1.511.451.371.161.16--1.36 mmol/LPTH1748710912912--65 ng/LPTHrP----7.91.4\<2 pmol/L

1.6. Strengths and limitations of our approach to this case {#s0035}
-----------------------------------------------------------

In this case report of a toddler with ESRD on peritoneal dialysis we highlight the complex pathophysiology of secondary hyperparathyroidism due to renal disease and the difficulties in maintaining normal calcium and phosphorus levels to promote optimal skeletal health. Children must maintain a positive calcium and phosphorus balance to meet the demands of a growing skeleton. However, treatment of secondary hyperparathyroidism must be undertaken cautiously to prevent hypercalcemia and its complications. Hypocalcemia is a common clinical presentation in patients with ESRD due to 1,25(OH)~2~D deficiency resulting in decreased intestinal calcium absorption and subsequent hypocalcemia. Hypercalcemia in patients with CKD on the other hand is an adverse effect of treatment of secondary hyperparathyroidism as illustrated in this case report. Other differential diagnosis for hypercalcemia in infants and children include parathyroid related disorders (multiple endocrine neoplasia (MEN) syndrome I and II, Jansen\'s metaphyseal chondrodyplasia), familial hypocalciuric hypercalciuria, Vitamin A and D intoxication, William\'s Syndrome, calcium sensing receptor disorders, granulomatous diseases and malignancy. We systematically ruled out inherited disorders, malignancy and granulomatous diseases in our patient. Two positive findings from our investigations were elevated vitamin A and PTHrP levels. Of note, caution is warranted in interpreting PTHrP levels in CKD as the carboxy terminal assay values are increased in patients with CKD. N terminal PTHrP assays must be performed to confirm the findings as we did in our patient.

1.7. Discussion of the relevant medical literature {#s0040}
--------------------------------------------------

In rare instances, hypercalcemia has been reported in infants with Congenital Anomalies of the Kidney and Urinary Tract (CAKUT). In a series of 99 patients with CAKUT, 15 patients were noted to have hypercalcemia in the absence of vitamin D or calcitriol treatment ([@bb0010]). Mean duration of hypercalcemia was 5.2 ± 6.0 months and mean corrected calcium was 12.3 mg/dl. Only 10 patients had PTH and 25OH D levels measured but PTHrP levels were not measured in this series. Elevated PTH levels were observed in 3/10 patients and increased 25OHD levels was observed in only 1 patient. To date, there are two case reports of hypercalcemia associated with increased PTHrP levels in children with CAKUT who are not on dialysis ([@bb0145]; [@bb0190]). Mechanisms by which PTHrP production is increased in CKD associated with CAKUT are unknown. In both case reports, malignancy was ruled out by imaging studies. Treatment of hypercalcemia in the above mentioned studies included hydration, furosemide, bisphosphonate therapy and reduced calcium intake. In our patient, we reduced dietary calcium intake with some clinical improvement but did not try other measures as our patient was on dialysis therapy.

1.8. Conclusions {#s0045}
----------------

This case illustrates the significant challenges faced in clinical practice in the management of CKD-MBD in children. This patient had severe CKD-MBD evidenced by multiple skeletal deformities and growth retardation. Treatment with calcitriol was initiated when PTH levels were significantly elevated (1458 ng/L) and patient had increased risk of high bone turnover disease from uncontrolled hyperparathyroidism. However, maintaining optimal PTH, calcium and phosphorus levels in a child with CKD while avoiding complications such as hypercalcemia proved to be difficult in this patient. Despite dietary interventions and discontinuation of calcitriol and ergocalciferol, patient had persistent hypercalcemia and overly suppressed PTH levels which increased the risk of low bone turn over disease. Our case was unique in that hypercalcemia developed acutely while the patient was hospitalized and persisted for several months till the time of kidney transplantation despite measures to treat hypercalcemia. Although calcitriol and vitamin D therapy may have aggravated hypercalcemia at the onset of clinical diagnosis, high PTHrP and vitamin A levels contributed to the persistently high calcium levels that corrected only after kidney transplantation. Management of CKD-MBD is particularly challenging in a child with increased demand for calcium and phosphorus to meet the needs of a growing dynamic skeleton on one hand but simultaneously avoiding overcompensation (i.e. oversuppressed PTH), hypercalcemia and ectopic calcifications of the cardiovascular system.

2. Introduction {#s0050}
===============

Calcium is the most abundant electrolyte in the human body, and in healthy adults, accounts for about 2%, or 1300 g, of body weight. From birth to approximately 20 years of age, when the skeleton reaches its full size and density, calcium content increases by some 40-fold ([@bb0310]). During this period, the increase in skeletal weight and calcium content requires the net retention of about 150 to 200 mg of calcium per day. Phosphorus accounts for about 0.6% of body weight at birth and about 1% of body weight, or 600 to 700 g, in the adult ([@bb0010]). Thus, in growing individuals, calcium and phosphorus balance must be positive to meet the needs of skeletal growth and consolidation. In adults, calcium and phosphorus balance is zero after peak bone mass is attained and becomes slightly negative as bone is slowly lost with aging. Calcium and phosphorus deficiency results in rickets in children and osteomalacia in both children and adults.

Vitamin D homeostasis is critical for control of calcium and phosphate balance in health and disease states. Circulating levels of the active form of vitamin D, 1,25 dihydroxyvitamin D (1,25(OH)~2~D) is largely determined by 1,25(OH)~2~D production in the kidney. In chronic kidney disease (CKD), vitamin D metabolism is perturbed contributing to CKD-associated mineral and bone disorder (CKD-MBD). The pathophysiology of CKD-MBD is complex and it involves the interactions between the hormones that regulate skeletal biology and calcium and phosphorus homeostasis. Parathyroid hormone (PTH), 1,25(OH)~2~D and fibroblast growth factor 23 (FGF23) are the principal regulators of bone and mineral homeostasis in CKD; as renal function declines, disruption of feedback loops between these hormones have adverse consequences on several organ systems, including the skeleton, heart and vascular system ([@bb0265]; [@bb0305]; [@bb0240]; [@bb0115]; [@bb0110]; [@bb0120]). Hence, treatment of patients with CKD-MBD is focused on restoring the feedback loops between PTH, 1,25(OH)~2~D and FGF23 to maintain normal calcium and phosphate homeostasis. This review will focus on the role of vitamin D in the pathophysiology and management of CKD-MBD.

2.1. Pathophysiology {#s0055}
--------------------

### 2.1.1. Vitamin D metabolism in health and kidney disease {#s0060}

As one of the principal hormonal regulators of calcium and phosphorus metabolism, 1,25(OH)~2~D is critically important for normal growth and mineralization of bone. The classical actions of 1,25(OH)~2~D are to stimulate calcium and phosphorus absorption from the intestine, thereby maintaining plasma concentrations at sufficient levels for normal growth and mineralization of bone. 1,25(OH)~2~D also has direct actions on bone, kidney, skin, parathyroid gland, and many other tissues unrelated to mineral metabolism ([@bb0125]).

Vitamin D exists as either ergocalciferol (vitamin D~2~) produced by plants, or cholecalciferol (vitamin D~3~) produced by animal tissues and by the action of near ultraviolet radiation on 7-dehydrocholesterol in human skin. Both forms of vitamin D are biologically inactive pro-hormones that must undergo successive hydroxylations at carbons \#25 and \#1 before they can bind to and activate the vitamin D receptor. The 25-hydroxylation of vitamin D occurs in the liver, catalyzed by one or more enzymes including the mitochondrial enzyme CYP27A1 and the microsomal enzyme CYP2R1 ([@bb0055]; [@bb0070]). The activity of hepatic 25-hydroxylation is not under tight physiologic regulation, and thus circulating concentrations of 25OHD are determined primarily by dietary intake of vitamin D and exposure to sunlight. Although 25OHD is the most abundant form of vitamin D in the blood, it has minimal capacity to bind to the vitamin D receptor and elicit a biologic response.

The active form of vitamin D, 1,25(OH)~2~D, is produced by the 1α-hydroxylation of 25OHD by the mitochondrial enzyme, 25-hydroxyvitamin D-1α-hydroxylase (1α-hydroxylase) ([@bb0130]; [@bb0135]). The circulating concentration of 1,25(OH)~2~D primarily reflects its synthesis in the proximal tubule of the kidney; however, 1α-hydroxylase activity also is found in keratinocytes, macrophages, and osteoblasts ([@bb0045]; [@bb0005]; [@bb0175]). 1α-Hydroxylation is the rate-limiting step in the bioactivation of vitamin D, and enzyme activity in the kidney is tightly regulated by PTH, calcium, phosphorus, 1,25(OH)~2~D and FGF23 ([@bb0170]; [@bb0060]; [@bb0235]; [@bb0250]). The other important vitamin D-metabolizing enzyme, the 25-hydroxyvitamin D-24-hydroxylase (24-hydroxylase), is found in kidney, intestine, lymphocytes, fibroblasts, bone, skin, macrophages, and possibly other tissues ([@bb0300]; [@bb0025]). The enzyme can catalyze the 24-hydroxylation of 25OHD to 24,25(OH)~2~D and that of 1,25(OH)~2~D to 1,24,25(OH)~3~D; both reactions initiate the metabolic inactivation of vitamin D via the C24-oxidation pathway. The kidney and intestine are major sites of hormonal inactivation of vitamin D by virtue of their abundant 24-hydroxylase activity.

FGF23 is a bone-derived circulating peptide that primarily acts on the kidney to regulate phosphate and vitamin D homeostasis. FGF23 inhibits renal tubular phosphate cotransport to induce phosphaturia and lower serum phosphorus concentrations. FGF23 suppresses the renal production and serum concentration of 1,25(OH)~2~D by suppressing 1α-hydroxylase mRNA and protein expression and stimulating 24-hydroxylase mRNA expression ([@bb0280]; [@bb0035]; [@bb0195]; [@bb0245]). In CKD, several human and animal studies have established that the primary reason for early 1,25(OH)~2~D deficiency is likely an increase in FGF23 levels rather than the actual loss of nephron mass which occurs in later stages of CKD ([@bb0150]; [@bb0255]; [@bb0180]; [@bb0165]). 1,25(OH)~2~D deficiency contributes to the pathogenesis of CKD-MBD including secondary hyperparathyroidism and abnormalities in the skeletal and cardiovascular system. Therefore, correction of 1,25(OH)~2~D deficiency is a key component of prevention and treatment for CKD-MBD.

### 2.1.2. CKD-MBD {#s0065}

Kidney Disease: Improving Global Outcomes (KDIGO) is an international organization established in 2003 to improve the care and outcomes of kidney disease patients worldwide. The term CKD-MBD was established in 2006 by KDIGO and is defined as a systemic disorder of mineral and bone metabolism due to CKD manifested by either one or a combination of the following: a) Abnormalities of calcium, phosphorus, PTH or vitamin D metabolism, b) Abnormalities of bone turnover, mineralization, volume, linear growth or strength, and, c) Vascular or other soft tissue calcification ([@bb0230]). Of note, the traditional term "renal osteodystrophy" is now exclusively used to define abnormalities in bone morphology associated with CKD and can only be made by bone biopsy ([@bb0015]).a)Abnormalities of calcium, phosphorus, PTH and vitamin D metabolism in CKD-MBD. Secondary hyperparathyroidism is a component of CKD-MBD, begins early in the course of CKD, and its prevalence increases as kidney function deteriorates. As glomerular filtration rate (GFR) declines, the earliest clinically detectable abnormality in the course of CKD in children ([@bb0255]) and adults ([@bb0180]) is a rise in plasma FGF23 levels. However, the mechanisms by which FGF23 production in bone increases in early CKD are poorly understood ([@bb0275]; [@bb0090]). Changes in FGF23 levels occur when GFR falls below 60 ml/min/1.73m^2^ and is followed by a decline in serum 1,25(OH)~2~D and subsequent rise in PTH levels when GFR falls below 50 ml/min/1.73m^2^. All of these changes occur long before increases in serum phosphorus levels and hypocalcemia are evident ([@bb0205]). Therefore, serum calcium and phosphorus levels are not reliable biomarkers for detection of early CKD-MBD. 1,25(OH)~2~D deficiency plays a major role in the development of secondary hyperparathyroidism by promoting parathyroid gland growth (hyperplasia) and increased PTH synthesis in part through loss of the ability to upregulate vitamin D receptor expression within parathyroid cells ([@bb0095]; [@bb0295]; [@bb0065]; [@bb0105]). Other factors that contribute to rise in PTH levels as renal function declines are hyperphosphatemia and hypocalcemia. With progressive loss of renal function, phosphate excretion is maintained by reducing the tubular reabsorption of filtered phosphate, an effect mediated by FGF23 and PTH. However, these beneficial adaptive increases in PTH and FGF23 to increase urinary phosphate excretion become maladaptive in the long term with adverse impact on the skeleton and cardiovascular system ([Fig. 3](#f0015){ref-type="fig"}).Fig. 3Pathophysiology of CKD-MBD.Fig. 3b)Abnormalities of bone turnover, mineralization and volume: role of vitamin D in skeletal complications related to CKD. The gold standard for the diagnosis and classification of renal osteodystrophy is bone biopsy. Bone pathology is described in terms of high, normal, or low bone turnover (T), mineralization (M) or volume (V) to provide a comprehensive assessment of bone quality as per KDIGO recommendations ([@bb0015]). The traditional types of renal osteodystrophy have been defined on the basis of turnover and mineralization as follows: mild renal osteodystrophy- slight increase in turnover and normal mineralization; osteitis fibrosa- increased turnover and normal mineralization; osteomalacia- decreased turnover and abnormal mineralization; adynamic bone- decreased turnover and acellularity; mixed, increased turnover with abnormal mineralization ([Table 3](#t0015){ref-type="table"}). However, in clinical practice bone biopsies are seldom performed and surrogate markers such as PTH, calcium and phosphorus are used to assess bone health and to guide therapy despite the fact that such markers are not sensitive or specific in diagnosing bone disease in CKD.Table 3Classification of renal osteodystrophy by bone histomorphometry.Table 3Characteristic featuresBone turnoverBone mineralizationBone volumeOsteitis fibrosa•Nl or ↑ ↑ osteoid volume•↑ ↑ osteoclast activity•↑ ↑ osteoclast number•↑ Fibrosis•↑ ↑ bone formation rate↑Normal↑, ↓ or normalMild HPT•Nl or ↑ osteoid volume•↑ osteoclast activity•↑ osteoclast number•↑ bone formation rateNormal or mild ↑Normal↑, ↓ or normalOsteomalacia•↑ ↑ osteoid volume•Nl or ↓ osteoclast activity•↓ osteoclast number•↓↓ bone formation rate↓Abnormal↑, ↓ or normalAdynamic•Nl or ↓ osteoid volume•↓ osteoclast activity•↓ osteoclast number•↓↓ bone formation rate↓Normal↑, ↓ or normal[^1]

In adults and children, bone disease develops as early as CKD stage 2 (GFR 60 to 89 mL/min/1.73 m^2^) ([@bb0305]; [@bb0160]; [@bb0030]; [@bb0085]; [@bb0225]; [@bb0080]; [@bb0075]). Bone biopsies in children with CKD 2--4 showed a lower serum calcium and higher PTH levels are associated with defective mineralization ([@bb0305]; [@bb0220]; [@bb0140]). Although, 1,25(OH)~2~D and 25OHD levels have been associated with lower cortical bone mineral density in patients with CKD by peripheral quantitative computed tomography (pQCT), these parameters are not useful to determine subtypes of bone disease ([@bb0100]). At the cellular level, 1,25(OH)~2~D plays a critical role in maintenance of skeletal health; 1,25(OH)~2~D regulates bone mineralization via control of calcium and phosphate homeostasis and regulation of PTH and FGF23 production. 1,25(OH)~2~D also has a direct effect on chondrocyte differentiation and function, bone mineralization, volume and turnover by virtue of its actions to regulate osteoblast and osteoclast activity ([@bb0040]). Thus in CKD, goal of treatment with vitamin D and calcitriol is to normalize calcium and phosphate homeostasis, suppress PTH and maintain optimal skeletal health.c)Vascular calcification: role of vitamin D in vascular complications related to CKD. Vascular calcifications develop early in CKD, and their prevalence increases as GFR declines such that approximately 80% of incident adult dialysis patients have evidence of coronary artery calcification ([@bb0050]; [@bb0260]). Calcification of vessels begins in pre dialysis CKD and mean serum phosphorus, calcium and PTH levels and dialysis duration have been associated with calcification scores and carotid intimal medial thickness in both children and adults ([@bb0290]; [@bb0270]; [@bb0285]). Across the spectrum of CKD, large observational studies in adults have shown that biochemical abnormalities of CKD-MBD, vascular calcification, and bone fragility are associated with increased risks for morbidity and mortality ([@bb0015]).

Pathophysiology of vascular calcification in CKD is unique in that the disease process is limited to tunica media of small and medium sized blood vessels compared to atherosclerosis which affects the general population where the disease process involves tunica intima of larger blood vessels. Pathognomonic findings of medial vascular calcification include osteochondrogenic differentiation and apoptosis of vascular smooth muscle cells, instability and release of extracellular vesicles loaded calcium and phosphate, and elastin degradation ([@bb0315]). Several systemic and local inhibitors and inducers of vascular calcification have been identified in rodent models of CKD including hypercalcemia and hyperphosphatemia. In vitro studies demonstrate that increasing extracellular concentrations of calcium and phosphate in the media activate signaling pathways that promote osteochondrogenic differentiation of vascular smooth muscle cells, induce apoptosis and formation of extracellular matrix vesicles that form the nidus for calcification. In rodent models of CKD, vitamin D receptor agonists (VDRA) decreased aortic calcification ([@bb0200]; [@bb0215]) and in vitro studies demonstrate that treatment with calcitriol and paricalcitol directly inhibit calcification induced by cocultures of vascular smooth muscle cells with macrophages ([@bb0210]). However, in humans with CKD, the role of VDRA therapy to prevent vascular calcifications remains controversial ([@bb0020]).

3. Diagnosis and treatment of CKD-MBD {#s0070}
=====================================

3.1. KDIGO guidelines {#s0075}
---------------------

Most recent KDIGO guidelines published in 2017 recommend monitoring serum levels of calcium, phosphate, PTH, and alkaline phosphatase activity beginning in CKD stage G3a (45--59 ml/min/1.73 m^2^) in adults, and CKD stage G2 (60--89 ml/min/1.73 m^2^)in children ([@bb0205]). However, sufficient clinical data is lacking to provide precise recommendations for target levels of calcium, phosphorus and PTH to maintain optimal bone health and prevent cardiovascular complications. Current recommendation is to evaluate modifiable factors when PTH levels were "above" the upper limit of normal and to initiate treatment when PTH levels are "progressively rising or persistently above the upper normal limit." The KDIGO guideline update provides the following rationale for its emphasis on not initiating treatment for a single elevated PTH value: (1) the optimal PTH concentration remains undefined; (2) a modest increase in PTH concentration is an appropriate adaptive response that contributes to phosphaturia in CKD and may therefore be beneficial for maintenance of normal serum phosphate levels as glomerular filtration rate (GFR) declines; and (3) resistance to skeletal effects of PTH may not necessitate correction of modestly elevated PTH to normal levels in CKD ([@bb0205]). The lack of specific evidence-based guidelines poses significant challenges in clinical practice to tailor therapy for CKD-MBD such that cardiovascular and skeletal complications can be minimized while optimizing therapy to maintain skeletal growth and integrity in children.

Current standard of care in CKD-MBD is to use a combined approach aimed at a) reducing serum phosphate concentrations by dietary phosphate restriction and phosphate binder therapy, b) maintaining normal serum calcium and suppressing PTH production by treatment with VDRAs or calcimimetics, and c) vitamin D supplementation to correct vitamin D deficiency. Of note, vitamin D deficiency is common in patients with CKD with \~30--60% prevalence rate in CKD stages 3--5 ([@bb0055]). Several studies have shown that administration of VDRAs such as calcitriol, paricalcitol, doxercalciferol, and alfacalcidol are effective in suppression of PTH levels in CKD. However, VDRA therapy in patients with CKD has not been proven to improve patient outcomes by randomized controlled trials. Additionally, superiority of a specific VDRA in its efficacy to suppress PTH concentrations has not been consistently demonstrated.

4. Future directions {#s0080}
====================

In patients with CKD, FGF23 excess contributes to the pathogenesis of CKD-MBD and is associated with increased cardiovascular risk and mortality ([@bb0120]; [@bb0185]; [@bb0155]). However, optimal FGF23 concentrations required to prevent such complications are yet to be established by clinical trials. Novel therapeutic strategies to reduce serum phosphorus and FGF23 concentrations in patients with CKD are currently under clinical investigation. These include therapies that combine dietary phosphate restriction with inhibitors of intestinal phosphate transport to effectively reduce both active and passive intestinal phosphate absorption. Challenges to treatment strategies that lower FGF23 concentrations in patients who have residual renal function include exacerbation of hyperphosphatemia (by attenuating the phosphaturic effect of FGF23) and potential worsening of hyperparathyroidism. Further studies are needed to establish optimal FGF23 and PTH targets for treatment and prevention of CKD-MBD.
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[^1]: Nl- Normal, ↓-low, ↑-high, HPT- hyperparathyroidism.
